PharmAla to supply Johns Hopkins Medicine for Clinical Trial - GlobeNewswire
PharmAla Biotech Holdings Inc. contracted as MDMA supplier for Johns Hopkins Medicine clinical trial. CEO Nicholas Kadysh highlights PharmAla's unique position to meet GMP MDMA quality standards. PharmAla terminates agreement with Red Light Holland on September 3, 2024. Selected to present novel molecule APA-01 at EBPS Workshop on September 26th. PharmAla focuses on research, development, and manufacturing of MDXX class molecules, including MDMA, aiming to alleviate global backlog and develop novel drugs.
Highlighted Terms
Related News
PharmAla Biotech Holdings Inc. contracted as MDMA supplier for Johns Hopkins Medicine clinical trial. CEO Nicholas Kadysh highlights PharmAla's unique position to meet GMP MDMA quality standards. PharmAla terminates agreement with Red Light Holland on September 3, 2024. Selected to present novel molecule APA-01 at EBPS Workshop on September 26th. PharmAla focuses on research, development, and manufacturing of MDXX class molecules, including MDMA, aiming to alleviate global backlog and develop novel drugs.